Form 4 for NVAX NOVAVAX INC
Accepted 2025-01-03 00:00:00 ET · period of report 2024-12-31 · accession 0001593968-25-000029 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-03 | 2024-12-31 | NVAX | Kelly James Patrick | EVP, CFO, Treas | M - OptEx | $0.00 | +35.0K | 49.5K | +241% | $0 |
| D | 2025-01-03 | 2024-12-31 | NVAX | Kelly James Patrick | EVP, CFO, Treas | F - Tax | $8.04 | -16.9K | 32.6K | -34% | -$135.9K |
| D | 2025-01-03 | 2024-12-31 | NVAX | Kelly James Patrick | EVP, CFO, Treas | M - OptEx | $0.00 | -35.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-31 | M | A | 35,000 | $0.00 | 49,508 | D | — | — | |
| 2 | Common | Common Stock | 2024-12-31 | F | D | 16,906 | $8.04 | 32,602 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2024-12-31 | M | D | 35,000 | $0.00 | 0 | D | $0.00 · — to 2033-09-12 | 35,000 Common Stock | (F1) The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vest with respect to one-half (1/2) of the RSUs on each of the first two (2) anniversaries of the grant date, in each case subject to continued employment with the Company through such vesting date. |